To the Editor: In the editorial accompanying the article by Rajkumar and colleagues (Dec. 21 issue)(1) on the results of the ORBITA-2 trial involving the use of percutaneous coronary intervention (PCI) in patients with stable angina, White(2) begins with a flawed premise: "The primary aim of treating patients with stable angina is to decrease symptoms and improve quality of life." That is not the primary aim of treating these patients. Relieving angina is important, but the real priority in the management of stable angina is the provision of appropriate medical therapy to reduce the risk of myocardial infarction and sudden . . .
A Placebo-Controlled Trial of PCI for Stable Angina
Baiardo Redaelli M.
2024-01-01
Abstract
To the Editor: In the editorial accompanying the article by Rajkumar and colleagues (Dec. 21 issue)(1) on the results of the ORBITA-2 trial involving the use of percutaneous coronary intervention (PCI) in patients with stable angina, White(2) begins with a flawed premise: "The primary aim of treating patients with stable angina is to decrease symptoms and improve quality of life." That is not the primary aim of treating these patients. Relieving angina is important, but the real priority in the management of stable angina is the provision of appropriate medical therapy to reduce the risk of myocardial infarction and sudden . . .I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.